Sign In
Buy INCR
$1.04
+0.0100 (+0.97%)
At Close: Jun 03, 2026
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
06:03pm, Thursday, 29'th Aug 2024
NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating result
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
08:54am, Wednesday, 28'th Aug 2024
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outsid
InterCure: A Cannabis Industry Leader Still Flying Under The Radar
03:42am, Sunday, 30'th Jun 2024
InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the
InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference
06:45am, Wednesday, 22'nd May 2024
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will part
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
08:27am, Wednesday, 01'st May 2024
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts
InterCure: Bargain Israel Cannabis Play
03:41pm, Monday, 22'nd Apr 2024
InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limite
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
11:58am, Friday, 22'nd Mar 2024
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside
PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape
12:12pm, Friday, 23'rd Feb 2024
LONDON--(BUSINESS WIRE)---- $INCR #CannG--The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), her
InterCure Provides an Update Regarding Nir Oz Facility
04:46pm, Tuesday, 13'th Feb 2024
NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
09:27am, Wednesday, 31'st Jan 2024
NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra
InterCure Wins Cannolam Arbitration Proceeding
04:39pm, Tuesday, 31'st Oct 2023
NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra
InterCure Provides an Update Regarding the Security Situation in Israel
05:04pm, Tuesday, 17'th Oct 2023
NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY
07:45pm, Thursday, 31'st Aug 2023
Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023
InterCure: Leader In Israel's Growing Medical Cannabis Market
07:22pm, Wednesday, 02'nd Aug 2023
In mid-August, InterCure, one of the leaders in the global medical cannabis market, will publish financial results for the 2nd quarter of 2023. According to the Ministry of Health, the consumption of
NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Compan y"), announced today that
